A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma

The present phase II study has demonstrated that augmenting neutrophil function by the addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin lymphoma while retaining the excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population for whom therapeutic options are limited owing to poor tolerance.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Plasmablastic lymphoma (PBL) is a rare type of non-Hodgkin lymphoma (NHL) with a predilection for the oral cavity. It is more commonly found in elderly patients infected with HIV and Epstein-Barr virus (EBV). Since PBL was first described in 1997,1 most cases have been described in HIV-positive patients.2 Some instances have been described in HIV-negative patients involving other organs; one third of these occurred in patients treated with some immunosuppressive therapy.3 The scarcity of presentations in HIV-negative patients and the overlapping features with multiple myeloma present a diagnostic and therapeutic challenge.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Primary cutaneous lymphomas are a heterogeneous group of lymphoid malignancies and are the second most common group of extranodal non-Hodgkin lymphoma (NHL) following gastrointestinal lymphomas.1 NHL involving the female genitalia is unusual, posing diagnostic and therapeutic challenges.2-4 Rare cases of vulvar NHL presenting as a vulvar mass were mostly diagnosed as diffuse large B-cell lymphoma and had an aggressive course.3,5 Cases of cutaneous T-cell lymphoma (CTCL) involving the vulva have been rarely reported.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Publication date: Available online 17 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ali Dehghanifard, Saeid Kaviani, Saeid Abroun, Mahshad Mehdizadeh, Sajedeh Saiedi, Amirhosein Maali, Sasan Ghaffari, Mehdi Azad Multiple myeloma (MM) results from malignancy in plasma cells and occurs at ages > 50 years. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes 1% of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as dexamethasone and bortezomib, it is still an incurable malignancy owing to the development o...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Peripheral blood stem cell transplantation (PBSCT) is an effective treatment for hematological malignancies. Mobilization of peripheral blood stem cells performs in different ways among transplantation centers. Since the Effects of lower CD34+ cells dose after low dose G-CSF induction on autologous stem cell transplantation outcomes are not studied much, so this study was performed for this purpose. 735 autologous stem cell transplanted patients with diagnoses of multiple myeloma (n  = 330), Hodgkin lymphoma (n = 200), non-Hodgkin lymphoma (n = 129), acute myeloid leukemia (n = 54) and solid tumors (n =...
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
Peripheral blood stem cell transplantation (PBSCT) is an effective treatment for hematological malignancies. Mobilization of peripheral blood stem cells performs in different ways among transplantation centers. Since the Effects of lower CD34+ cells dose after low dose G-CSF induction on autologous stem cell transplantation outcomes are not studied much, so this study was performed for this purpose. 735 autologous stem cell transplanted patients with diagnoses of multiple myeloma (n  = 330), Hodgkin lymphoma (n = 200), non-Hodgkin lymphoma (n = 129), acute myeloid leukemia (n = 54) and solid tumors (n =...
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
Publication date: Available online 17 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ali Dehghanifard, Saeid Kaviani, Saeid Abroun, Mahshad Mehdizadeh, Sajedeh Saiedi, Amirhosein Maali, Sasan Ghaffari, Mehdi Azad Multiple myeloma (MM) results from malignancy in plasma cells and occurs at the ages over 50. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes one percent of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as Dexamethasone (DEX) and Bortezomib (BTZ), it is still an incurable malignancy due to ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Multiple myeloma (MM) results from malignancy in plasma cells and occurs at ages> 50 years. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes 1% of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as dexamethasone and bortezomib, it is still an incurable malignancy owing to the development of drug resistance. The tumor cells develop resistance to apoptosis, resulting in greater cell survival, and, ultimately, develop drug resistance by changing the various signaling pathways involved in cell proliferation, survival, differ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
Conclusion VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL. Micro-Abstract We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacious with chemotherapy with complete response rate of 83% and 1-year event-free survival of 83%. VOR did not significantly alter chemotherapy steady-state concentrations, CD4+ cell counts, or HIV viral loads.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our results are encouraging and justify evaluation of TECAM versus BEAM (carmustine, etoposide, cytarabine, melphalan) in a prospective multicenter study in a large homogenous patient population. Micro-Abstract High-dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed lymphoma. We retrospectively analyzed the data from 212 lymphoma patients who had undergone ASCT with the TECAM conditioning regimen. The 3-year overall survival, progression-free survival, and death resulting from treatment were comparable to those reported with other conditioning regimens....
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: - Nonmesothelial neoplasms are uncommon in individuals with MM, but certain tumor types are increased in prevalence. In an unselected study population with respect to BAP1 status, the prevalence of several tumor types described in BAP1 mutation carriers, including lung carcinoma, clear cell renal cell carcinoma, breast carcinoma, meningioma, pleomorphic undifferentiated sarcoma, and ocular melanoma, was increased. PMID: 29528717 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Rituxan | Study